Arginine Replacement Therapy in COVID-19
ConditionCOVID-19
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age3-21
SponsorEmory University
About this trial
This study aims to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19.
The study will be performed at the Children's Healthcare of Atlanta, Arthur M. Blank Hospital. Patients will be randomized to receive one of three doses of arginine three times a day for five days or at discharge whichever comes first.
Eligibility criteria
Qualifiers
Established diagnosis of COVID-19 requiring admission to the hospital for treatment of COVID-19 infection
Age 3 years - 21 years of age
Disqualifiers
Severe hepatic dysfunction: ALT> 6 x Upper limit of normal
Renal dysfunction: Creatinine > 1.5 x upper limit of normal or on dialysis
Acute Stroke
Pregnancy
Trial design
Treatments tested in this trial
- Arginine Hydrochloride
Treatment groups
21 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov